These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26659127)

  • 1. A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells.
    Solomon BJ; Desai J; Rosenthal M; McArthur GA; Pattison ST; Pattison SL; MacDiarmid J; Brahmbhatt H; Scott AM
    PLoS One; 2015; 10(12):e0144559. PubMed ID: 26659127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
    Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.
    MacDiarmid JA; Langova V; Bailey D; Pattison ST; Pattison SL; Christensen N; Armstrong LR; Brahmbhatt VN; Smolarczyk K; Harrison MT; Costa M; Mugridge NB; Sedliarou I; Grimes NA; Kiss DL; Stillman B; Hann CL; Gallia GL; Graham RM; Brahmbhatt H
    PLoS One; 2016; 11(4):e0151832. PubMed ID: 27050167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
    Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA
    J Clin Neurosci; 2015 Dec; 22(12):1889-94. PubMed ID: 26279503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
    Northfelt DW; Ramanathan RK; Cohen PA; Von Hoff DD; Weiss GJ; Dietsch GN; Manjarrez KL; Randall TD; Hershberg RM
    Clin Cancer Res; 2014 Jul; 20(14):3683-91. PubMed ID: 24807889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors.
    Murakami H; Ikeda M; Okusaka T; Inaba Y; Iguchi H; Yagawa K; Yamamoto N
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):631-9. PubMed ID: 26223436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
    Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
    Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
    Kiewe P; Hasmüller S; Kahlert S; Heinrigs M; Rack B; Marmé A; Korfel A; Jäger M; Lindhofer H; Sommer H; Thiel E; Untch M
    Clin Cancer Res; 2006 May; 12(10):3085-91. PubMed ID: 16707606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.
    Vukelja SJ; Anthony SP; Arseneau JC; Berman BS; Cunningham CC; Nemunaitis JJ; Samlowski WE; Fowers KD
    Anticancer Drugs; 2007 Mar; 18(3):283-9. PubMed ID: 17264760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
    Forero A; Meredith RF; Khazaeli MB; Shen S; Grizzle WE; Carey D; Busby E; LoBuglio AF; Robert F
    Cancer Biother Radiopharm; 2005 Oct; 20(5):467-78. PubMed ID: 16248762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.